Armand Butera

Though limited data exist, Dr. Dunfaif believes there’s are indications of cardiovascular risk in patients of all ages with polycystic ovary syndrome.

From evidence-based and plant-based diets, to promising new strategies involving SGLT2 inhibitors, Dr. Taub detailed preventative strategies used to combat cardiovascular disease.

Dr. Grunberger believes that the improved time in range brought on by continual glucose monitoring could lead to a reduction in hypoglycemia and risk of cardiovascular events, as well as promising monetary benefits for patients and payers.

While some treatments did not result in reduced instances of strokes in patients, others such as GLP-1 agonists provided Dr. Inzucchi with new opportunities for cardiovascular disease prevention.

Dr. Donna H. Ryan presents data on emerging pharmacological strategies that could aid patients in achieving optimal weight loss and prevent risk of cardiovascular events and diabetes.

Despite having lower burden of several cardiovasculard disease risk factors, cardiovascular mortality is higher in African Americans, which Dr. Dagogo-Jack attributes to disparities in patient care.

Dr. Peter Grant admits that the phenotypes surrounding certain cardiovascular diseases are complex, but notes treatments can be recommended based on individual patients’ complications.

Dr. Chovatiya speaks on the advancements made in vitiligo research, how the disease can disproportionately impact patients of different ethnicities, and how each patient can be properly treated.

In his presentation at TMIOA, Dr. Inzucchi referenced several diabetes medications and glucose management methods that resulted in a reduction of stroke risk in patients.

In an interview with HCPLive, Dr. Jean-Pierre Llanos-Ackert and Dr. Bill Cook discuss how tezepelumab resulted in improved lung function and an 86% reduction in exacerbation rates in this patient population.

A rarity in biologic treatments for patients with moderate-to-severe plaque psoriasis, Dr. Miller notes that patients treated with guselkumab recorded overwhelmingly positive PASI scores.

Despite cautionary programs and air purifiers having been installed in the school to alleviate allergic symptoms, investigators found they did not significantly reduce symptom-days.

As with previous studies, the investigators found that the biologic aided in reducing severe exacerbations and improving lung function in patients with evidence type 2 inflammation.

Investigators believe the current climate crisis can lead to an increased risk of COPD exacerbations and mortality rates, both of which have been noted in prior research.

In an interview with HCPLive, Rosenberger mentioned that every conversation with a patient is an opportunity to educate them on their potential allergies and treatment methods, especially at a time when concerns regarding the delta variant are prominent.

A new study sheds light on some of the atopic disease risks that are associated with early childhood and continue into midlife.

Investigators push for a greater understanding of the disease in relation to the mental health of young patients, which has affected roughly 20% of the global pediatric population.

The move comes amid delays in FDA approvals for multiple JAK inhibitors for the treatment of rheumatic conditions.

The US Food and Drug Association are also requiring new and updated warnings for baricitinib and upadacitinib, 2 other arthritis medicines in the same drug class as tofacitinib.

Investigators urge patients undergoing hemodialysis to adhere to their COVID-19 vaccination schedules, as data show a low antibody response.

Investigators believe the ALDORADO trial could properly diagnose the accuracy of open food challenges in comparison to the traditionally used double-blind placebo-controlled food challenge in pediatric patients with food allergies.

Investigators hope that the emerging method of managing these atopic diseases can help remove racial and socioeconomic barriers to care.

Despite conflicting data, investigators form Spain found that gastroesophageal reflux disease and asthma are bidirectional, with each disease exacerbating each other.

Investigators report that the small number of adverse events from the vaccine were successfully treated, with the remaining participants experiencing no allergic responses.

Investigators found no significant differences in the efficacy and safety of the originator or biosimilars in children with juvenile idiopathic arthritis.

Despite conflicting evidence surrounding older patient populations, investigators found no age-specific treatment effects on major cardiovascular outcomes.

Recent phase 3 trial data confirms that dupilumab is the first biologic medicine is the first to reduce severity and symptoms of atopic dermatitis in pediatric patients.

Investigators find that substitute salt better protects older people with a history of stroke or high blood pressure against secondary outcomes of cardiovascular events and death.

A recent study found no benefits of immediate angiography over a delayed or selective strategy with respect to the 30-day risk of death from any cause.

Investigators argue that outdated practice laws and other methods hinder physician assistants and nurse practitioners from providing the best patient care and utilizing their skills during the COVID-19 pandemic.